The FDA enforcement report lists a Class II recall of carbamazepine 200 mg tablets in 100- and 1,000-count bottles from Golden State Medical Supply. The reason is a manufacturing (CGMP) deviation: tablets with black specks. The recall is ongoing and was posted on 26 August 2026.
Class II means temporary or reversible harm is possible but serious harm is unlikely. This is a quality defect in one distributor's product, not a finding about carbamazepine.
The product is a US supply. For patients anywhere, the relevant message is the one that matters for every antiseizure drug: do not stop carbamazepine abruptly because of a recall notice. A patient worried about their tablets should get a replacement supply first.
- This recall affects one US distributor's carbamazepine 200 mg bottles
- Tell patients never to stop carbamazepine suddenly because of a recall
- Swap to an unaffected supply before discarding tablets
- Report visibly defective tablets to the dispensing pharmacy
Why it matters
Recall notices can prompt patients to stop antiseizure drugs abruptly, which is the real clinical risk.
Don't overread it
This is a manufacturing quality issue with one supply, not a safety signal for carbamazepine.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free